Nasdaq · CIK 0001783328
TCRX TScan Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing 10 d ago. Close $0.24 on Oct 9, 2026, +4% from the 52-week low and -91% from the high.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
6
with a Form 4 at this company
Price and insider trades, last year
TCRXOct 9, 2026 · close 0.24
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at TScan Therapeutics, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 46Moderate | Lynx1 Capital Management LP owner buy | $3.1M 2,588,794 shares | +48% | +13% from low-79% from high | |
| 28Weak | Lynx1 Capital Management LP owner buy | $386k 131,800 shares | +3% | - | |
| 2Weak | Lynx1 Capital Management LP owner buy | $4,114 947 shares | +0% | - |
Transactions
The last 12 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 1, 2026 | Gavin MacBeath Chief Executive Officer | AGrant or award Voting Common Stock | +1,000,000 | $0.00 | $0 | 1,049,767 | 10 d ago |
| Oct 1, 2026 | Zoran Zdraveski See Remarks | AGrant or award Voting Common Stock | +300,000 | $0.00 | $0 | 304,716 | 10 d ago |
| Jun 30, 2025 | Baker Bros. Advisors LP director | AGrant or award Non- Qualified Stock Option (right to buy)derivativeindirect: See Footnotes | +67,000 | $0.00 | $0 | 67,000 | Jul 2, 2025 |
| Jun 30, 2025 | Baker Bros. Advisors LP director | AGrant or award Non- Qualified Stock Option (right to buy)derivativeindirect: See Footnotes | +67,000 | $0.00 | $0 | 67,000 | Jul 2, 2025 |
| May 19, 2025 | Lynx1 Capital Management LP owner | POpen-market purchase Common stock, $0.0001 par value per share ("Common Stock")indirect: See footnote | +1,388,794 | $1.20 | $1.7M | 6,746,141 | May 21, 2025 |
| May 20, 2025 | Lynx1 Capital Management LP owner | POpen-market purchase Common Stockindirect: See footnote | +1,200,000 | $1.20 | $1.4M | 7,946,141 | May 21, 2025 |
| Jan 3, 2025 | Jason Amello Chief Financial Officer | AGrant or award Stock Option (Right to Buy)derivative | +270,000 | $0.00 | $0 | 270,000 | Feb 11, 2025 |
| Jan 12, 2024 | Leiden Dworak other | AGrant or award Stock Option (Right to Buy)derivative | +46,875 | $0.00 | $0 | 46,875 | Feb 11, 2025 |
| Dec 26, 2024 | Lynx1 Capital Management LP owner | POpen-market purchase Pre-funded Warrant (right to buy)derivativeindirect: See footnote | +7,500,000 | $4.00 | $30M | 7,500,000 | Dec 30, 2024 |
| Dec 12, 2024 | Lynx1 Capital Management LP owner | POpen-market purchase Common stock, $0.0001 par value per share ("Common Stock")indirect: See footnote | +31,800 | $3.01 | $96k | 5,257,347 | Dec 16, 2024 |
| Dec 13, 2024 | Lynx1 Capital Management LP owner | POpen-market purchase Common Stockindirect: See footnote | +100,000 | $2.90 | $290k | 5,357,347 | Dec 16, 2024 |
| Nov 15, 2024 | Lynx1 Capital Management LP owner | POpen-market purchase Common stock, $0.0001 par value per shareindirect: See footnote | +947 | $4.34 | $4,114 | 5,225,547 | Nov 19, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Jason AmelloChief Financial Officer
- Baker Bros. Advisors LPdirector, owner, other
- Leiden Dworakother
- Lynx1 Capital Management LPowner
- Gavin MacBeathChief Executive Officer
- Zoran ZdraveskiSee Remarks
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.